{"entity":{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","aka":[],"tldr":"Full-Life Technologies makes medicines that carry a strongly radioactive particle, actinium-225, onto cancer cells so the radiation acts at short range. Its lead medicine is being tested in advanced prostate cancer and a second in lung and other solid tumours.","summary":"Full-Life Technologies Limited describes itself as a privately held, fully integrated, clinical-stage actinium-based radiopharmaceutical company with operations in Belgium, Germany and China; its website description gives Shanghai as headquarters, and the trial sponsor is its UK subsidiary, Full-Life Technologies UK Limited. It attaches radionuclides to peptides, small molecules and single-domain antibodies. [225Ac]Ac-FL-020, a PSMA-targeted alpha radioconjugate, is in a global phase 1 trial in metastatic castration-resistant prostate cancer (NCT06492122), using an indium-111 labelled version for dosimetry; the company reported preliminary safety and PSA decline data at ESMO in October 2026. [225Ac]Ac-FL-261 targets c-MET and received US FDA IND clearance and Australian clearance in September 2026 for a phase 1/2 trial (NCT07873450) in c-MET overexpressing solid tumours, with an initial focus on non-squamous non-small cell lung cancer. A third, NTSR1-targeted small-molecule radioconjugate is in phase 1 under a collaboration with a partner, and earlier programmes target NPY1R and B7-H3. In August 2026 it completed construction of an actinium-225 manufacturing and radiolabelling facility in Gembloux, Belgium. Its first registered cancer trial, NCT06492122, was posted on ClinicalTrials.gov in July 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.full-life.com/"},{"label":"About Full-Life","url":"https://www.full-life.com/about-us"},{"label":"Pipeline","url":"https://www.full-life.com/radio/pipeline"},{"label":"Press releases","url":"https://www.full-life.com/media/press-releases"},{"label":"ClinicalTrials.gov: phase 1 trial of [225Ac]Ac-FL-020 (NCT06492122)","url":"https://clinicaltrials.gov/study/NCT06492122"},{"label":"ClinicalTrials.gov: SumMET phase 1/2 trial of [225Ac]Ac-FL-261 (NCT07873450)","url":"https://clinicaltrials.gov/study/NCT07873450"}],"tags":[],"related":[],"cancers":["prostate-mcrpc","nsclc"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy","radioligand-therapy","actinium-225-supply"],"targets":["psma","met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read on 29 October 2026; the milestones page did not render.","Headquarters is taken from the site's own description ('headquartered in Shanghai, China with operations in Europe'); the overview page lists operations in Belgium, Germany and China, and recent releases are datelined London.","No financing round is recorded because no company release with an amount was read.","The ESMO 2026 FL-020 data were announced as encouraging; the numbers were not read."],"hq":"Shanghai","country":"CN","companyType":"radiopharma","website":"https://www.full-life.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/full-life-technologies/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}]}}